Site search

Clear filter
2957 results for '' found
COALA Trial: Changing Outcomes After Low Anterior resection in colorectal cancer by anal sphincter prehabilitation prior to reversal of ileostomy – a parallel explanatory (COALA-1) and pragmatic
COALA Trial: Changing Outcomes After Low Anterior resection in colorectal cancer by anal sphincter prehabilitation prior to reversal of ileostomy – a parallel explanatory (COALA-1) and pragmatic
/
A Phase Ib, multicenter, open-label platform study of select drug combinations in adult patients with lower risk (very low, low, or intermediate risk) myelodysplastic syndrome (NCT04810611)
A Phase Ib, multicenter, open-label platform study of select drug combinations in adult patients with lower risk (very low, low, or intermediate risk) myelodysplastic syndrome (NCT04810611)
/
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in C
/
A randomized, double-blind, double-dummy, placebocontrolled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period
A randomized, double-blind, double-dummy, placebocontrolled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period
/
A randomized, open-label, parallel-group, non-inferiority study comparing efficacy, safety, and tolerability of remibrutinib after switching from ocrelizumab in participants living with relapsing
A randomized, open-label, parallel-group, non-inferiority study comparing efficacy, safety, and tolerability of remibrutinib after switching from ocrelizumab in participants living with relapsing
/
A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Immunoregulatory Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination with Pembrolizum
A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Immunoregulatory Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination with Pembrolizum
/
BIO|CONCEPT.CorSky Family (NCT05610176)
/
An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEXX) (N
/
A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophre
/
D-Cycloserine Augmentation of Intermittent Theta Burst Stimulation (iTBS) in Depression (COGENT): A Multi-Site, Randomised, Placebo-Controlled Trial (ACTRN12622001359729)
/
66 67 68 69 70